martes, 28 de julio de 2026
Oral Cancer Screening in Rural Hungary Detects Lesions but Follow-Up Remains Low Edited by Gargi Mukherjee
https://www.medscape.com/viewarticle/oral-cancer-screening-rural-hungary-detects-lesions-follow-2026a1000pe4?src=
Mobile screening units in rural Hungary identified oral mucosal lesions in 1 in 20 adults screened between June 2021 and March 2023; however, only 3.8% of those who screened positive attended specialist follow-up, resulting in six confirmed malignant neoplasms
Childhood Cancer Incidence Is Associated With Socioeconomic Status Evra Taylor
https://www.medscape.com/viewarticle/childhood-cancer-incidence-associated-socioeconomic-status-2026a1000pgu?src=
The incidence of childhood cancer is as much as 15% higher in the least marginalized neighborhoods than in the most marginalized areas, a study suggests.
EMA Recommends New Hematology and Supportive Care Drugs Edited by Zeel Mehta
https://www.medscape.com/viewarticle/ema-recommends-new-hematology-and-neutropenia-drugs-2026a1000peb?src=
Two established hematology-oncology treatments, a generic ruxolitinib and a pegfilgrastim biosimilar, moved closer to EU approval after the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued positive opinions for both at its July meeting.
New European Hodgkin Lymphoma Guidelines Update Management Dr Elisa Riera
https://www.medscape.com/viewarticle/new-european-hodgkin-lymphoma-guidelines-update-management-2026a1000pdv?src=
The European Hematology Association has published its 2026 clinical practice guidelines for the diagnosis, treatment, and follow-up of Hodgkin lymphoma. This document standardizes the management of a malignant neoplasm of lymphoid origin that primarily affects young adults, with a second peak in incidence among people older than 55 years.
ACE Inhibitors vs ARBs: Long-Term Cancer Risk Varies July 28, 2026
https://www.medscape.com/viewarticle/ace-inhibitors-vs-arbs-long-term-cancer-risk-varies-2026a1000pij?src=
Patients treated exclusively with angiotensin-converting enzyme inhibitors (ACEIs) had lower overall cancer incidence than those treated exclusively with angiotensin receptor blockers (ARBs) over 23 years of follow-up. ACEI therapy was linked to lower odds for breast, prostate, melanoma, non-Hodgkin lymphoma, kidney, and colorectal cancers, but higher odds for lung, bladder, and pancreatic cancers.
Viewpoint: High-dose resveratrol supplements to extend health and life? Don’t waste your money. Joe Schwarcz | July 27, 2026
https://geneticliteracyproject.org/2026/07/27/viewpoint-high-dose-resveratrol-supplements-to-extend-health-and-life-dont-waste-your-money/
A quick online search for “resveratrol supplements” finds dozens produced by various companies. They contain anywhere from 50 to 500 mg resveratrol per capsule and sport labels that scream “source of antioxidants.” But there is no mention of any condition that resveratrol is expected to treat or prevent. For good reason! While there is plenty of speculation about what this compound can do based on laboratory experiments that use cell cultures, yeasts, worms, flies or rodents, it is best to remember that humans are not giant test tubes or colossal rodents. Clinical evidence for any benefit of resveratrol supplements in people is sparse, but there are some interesting possibilities as researchers aim to develop special formulations of resveratrol that increase its absorption and therefore levels in the blood previously not achievable.
Three Cancer Drugs Advance Toward Broader EU Use Edited by Joyani Das
https://www.medscape.com/viewarticle/three-cancer-drugs-advance-toward-broader-eu-use-2026a1000pn1?src=
Three established cancer therapies — Enhertu (trastuzumab deruxtecan, Daiichi Sankyo Europe), Piqray (alpelisib, Novartis Europharm), and Trodelvy (sacituzumab govitecan, Gilead Sciences) — moved closer to expanded use in the EU after the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended extensions of indication for all three at its July 2026 meeting.
The Clues Hidden in Failed Prostate Cancer Immunotherapy Trials David Brzostowicki July 28, 2026
https://www.medscape.com/viewarticle/clues-hidden-failed-prostate-cancer-immunotherapy-trials-2026a1000phy
Emmanuel S. Antonarakis, MD, recently spent thousands of dollars profiling the immune cells of a single patient whose prostate cancer disappeared after immunotherapy — an outcome that once seemed impossible. The experiment wasn’t meant to show that immunotherapy had worked in prostate cancer. It was meant to explain why, against all expectations, it already had.
Results From the PROGRESS Study of Zilurgisertib in Patients With Fibrodysplasia Ossificans Progressiva by Madaline Spencer| Published on: Jul 27, 2026
Results From the PROGRESS Study of Zilurgisertib in Patients With Fibrodysplasia Ossificans Progressiva
by Madaline Spencer| Published on: Jul 27, 2026
Joanne Quan, MD, Chief Medical Officer of Mirum Pharmaceuticals, discusses results from the PROGRESS study of zilurgisertib in patients with fibrodysplasia ossificans progressiva (FOP).
https://checkrare.com/results-from-the-progress-study-of-zilurgisertib-in-patients-with-fibrodysplasia-ossificans-progressiva/
FDA Approves Jideytro (Zidesamtinib) for Adults With ROS1-Positive Non-Small Cell Lung Cancer by Madaline Spencer| Published on: Jul 27, 2026
https://checkrare.com/fda-approves-jideytro-zidesamtinib-for-adults-with-ros1-positive-non-small-cell-lung-cancer/
The US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have received a prior ROS1 kinase inhibitor.
Going Beyond Lab Values: Cognitive Impairment in Patients With Immune Thrombocytopenia by Madaline Spencer| Published on: Jul 28, 2026
Going Beyond Lab Values: Cognitive Impairment in Patients With Immune Thrombocytopenia
by Madaline Spencer| Published on: Jul 28, 2026
David Kuter, MD, DPhil, Director of Clinical Hematology at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School, discusses cognitive impairment in patients with immune thrombocytopenia (ITP).
https://checkrare.com/going-beyond-lab-values-cognitive-impairment-in-patients-with-immune-thrombocytopenia/
The Lancet HIV Commission on ageing and HIV +...
https://www.thelancet.com/commissions-do/ageing-and-hiv?dgcid=hubspot_email_conferencealerts_lanhivageing26&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-_jrn1fBNmVQGlja1nePFZcla9gNnGcqS_JJDuzap_H8ZGbM7X0bYkgRuYzQsxk1Z0o3ZkApk3UwriAcWfHet9wzWiM9Q&_hsmi=429942973&utm_content=429942973&utm_source=hs_email
As the number of people living with HIV aged 50 years and older continues to increase, prevention, treatment, and health systems must adapt to support lifelong health and wellbeing. Supporting healthy ageing requires more than sustained viral suppression; it requires care that is informed by what matters most to the individual, with attention to maintaining physical and mental function, minimising healthcare complexity, and addressing multimorbidity, polypharmacy, stigma, and social determinants of health. Bringing together clinical evidence, modelling, policy perspectives, and community voices, this Commission outlines the changes needed to ensure that the millions of people living with HIV can age well.
Indigenous-led cancer control The Lancet Oncology +... + +
https://www.thelancet.com/journals/lanonc/issue/vol27no8/PIIS1470-2045(26)X2007-1
Indigenous-led cancer control
The Lancet Oncology
Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research
Babita Kataria, DMa ∙ Asima Mukhopadhyay, MDb ∙ Ana Oaknin, MDc ∙ Dearbhaile M O'Donnell, MDd ∙ David S P Tan, MDe ∙ Prof David Cibula, MDf ∙ et al.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00215-9/abstract?dgcid=raven_jbs_etoc_feature_lanonc
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial
Prof Herui Yao, MDa,* ∙ Prof Qingyuan Zhang, MDb,* ∙ Prof Huiping Li, MDc,* ∙ Prof Yongmei Yin, MD*,d ∙ Prof Shusen Wang, MD*,e ∙ Prof Quchang Ouyang, MDf,* ∙ et al.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00193-2/abstract?dgcid=raven_jbs_etoc_feature_lanonc
Optimising health care for adults with Down syndrome The Lancet Healthy Longevity +... +
Optimising health care for adults with Down syndrome
The Lancet Healthy Longevity
https://www.thelancet.com/journals/lanhl/issue/vol7no6/PIIS2666-7568(26)X2006-2
Associations of testosterone, sex hormone-binding globulin, and related hormones with risks of cancer death, incident cancer, and incident prostate cancer in men: individual participant data meta-analyses
Ross J Marriott, PhDa ∙ Kevin Murray, PhDa ∙ Leen Antonio, MD PhDc ∙ Prof Robert J Adams, MBBS MDd ∙ Prof Christie M Ballantyne, MDe ∙ Prof Douglas C Bauer, MDf ∙ et al.
https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(26)00041-3/fulltext?dgcid=raven_jbs_etoc_feature_lanhl
SMA: why adult support must keep up with medical progress + + +
https://rarerevolutionmagazine.com/sma-why-adult-support-must-keep-up-with-medical-progress/
Lassi Murto was diagnosed with spinal muscular atrophy as a child and is now navigating adult life with SMA. He shares his experience of what it is like when the systems around a condition don’t match the medical progress and improved prognosis this brings
Written by Lassi Murto, chair of SMA Finland
Understanding comes first.
Decisions follow.
Your clinical trial navigation hub, guiding you with decision support, every step of the way.
https://app.trialport.com/?utm_campaign=RareRevITP&condition=259
For a child with severe epidermolysis bullosa (EB), wound care can take hours every week, sometimes daily. Who carries that work shapes not only how the disease is managed, but who the family becomes around it. Ryan Hultman and his wife Renata, Vancouver, Canada, have led their daughter Raquel’s dressing changes for fifteen years. Angélique Sauvestre, mother to Amélie, and based in France, has built her advocacy on the conviction that no parent should be expected to. The two paths look very different. The parents at the end of them say the same thing: that all roads lead to judgment‑free, personal choice.
https://editions.rarerevolutionmagazine.com/html5/reader/production/default.aspx?pubname=&edid=e0508b93-1cde-4785-b9ae-c36724bde55a&pnum=26
Do we need T cells to achieve deep B cell depletion? As deep B cell depletion moves into autoimmune disease, antibody-directed allogeneic NK cell therapy may offer a different path to potency, scalability, and outpatient treatment. Written byFred Aslan
https://www.drugdiscoverynews.com/do-we-need-t-cells-to-achieve-deep-b-cell-depletion-17396
The most important debate in autoimmune cell therapy is no longer whether deep B cell depletion can reset the immune system, as CAR T therapy has helped settle that question. The harder question is how to deliver and achieve this effect safely, reproducibly, and practically at scale.
One dose of new gene therapy could reduce tau protein throughout brain Voyager Therapeutics’ promising toxicology data in non-human primates suggests their proprietary capsid technology could deliver long-lasting results in Alzheimer’s disease. Written byAllison Whitten, PhD
https://www.drugdiscoverynews.com/one-dose-of-new-gene-therapy-could-reduce-tau-protein-throughout-brain-17378?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_BaLdDd869QGd4SsxZR5R1pJAcOeDmK92JQ7YaGVGAf2lwIajJ1LGQ9WruBjGC_PCyba5G0svYZbHL6CzzEOP7_4Q_yQ&_hsmi=430295917&utm_content=430295917&utm_source=hs_email
Tau-targeting therapies focus on ridding the brain of the toxic tau protein that wreaks havoc in neurodegenerative diseases like Alzheimer’s disease (AD). Drugs currently under investigation to target tau include immunotherapies, small molecule tau inhibitors, antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs) and gene therapy. Gene therapy options, in particular, have the exciting potential to offer broad and durable reductions in tau in just one dose.
How small molecule tau inhibitors could treat Alzheimer’s disease
While amyloid plaques form first, new work suggests targeting tau tangles that spread through the brain could also help the fight against this devastating disease.
Written byAllison Whitten, PhD
https://www.drugdiscoverynews.com/how-small-molecule-tau-inhibitors-could-treat-alzheimer-s-disease-16849?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-88Ww_WpM_AZDMP2mK7Fd9gpxGEmaCD-BDQDNvzZbIBw43SSQ8h-P9etgLQHCCneOzKxkLmdgYtJFhdr3HB0GXJjgeCcg&_hsmi=430295917&utm_content=430295917&utm_source=hs_email
Why Oropouche Virus Is Gaining Global Attention David García Pérez July 24, 2026
https://www.medscape.com/viewarticle/why-oropouche-virus-gaining-global-attention-2026a1000p3l?ecd=WNL_trdalrt_pos1_ous_260728_etid8545247&uac=148436CN&impID=8545247
Once considered a little-known pathogen largely confined to the Amazon region, the Oropouche virus has emerged as a growing public health threat across Latin America. A major outbreak in Brazil in 2023, which resulted in more than 30,000 reported cases, rapid spread throughout the country, and the first confirmed death associated with the disease, prompted the World Health Organization to call for urgent prevention and control measures.
Spatial proteogenomics in oncology: linking molecular positivity to tissue context Haiyue You [1,2,†] , Yida Wang [2,3,†] , Xinfeng Yang [1,2,†] , Feng Zhang [2,3] , Yan Zhang* [1,2,3
https://www.academia.edu/2998-7741/3/3/10.20935/AcadOnco8440
Tumor biomarker assessment has traditionally focused on two simple questions: whether a marker is expressed and how strongly it is expressed. This method can still be useful but it is no longer sufficient. The meaning of a marker may vary according to its tissue location, neighboring cell types, and association with a treatment-related microenvironment. As spatial omics technologies progress, cancer research is moving beyond a simple positive-or-negative interpretation of molecular markers. It is therefore important to ask where a marker is positive, which cells are nearby, and whether it is part of an active tissue structure. Spatial proteogenomics brings together protein measurements, transcriptomics, spatial tissue imaging and bioinformatics. This allows for the integration of molecular state, cell state and spatial information. This mini review discusses what this change means for oncology. It focuses on the spatial chain of evidence, the tumor microenvironment, spatial functional units, and the challenge of turning spatial maps into measurements that can be used in the clinic.
https://www.academia.edu/journals/academia-oncology/articles?source=journal-top-nav
FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol First oral PCSK9 inhibitor provides an additional treatment option for adults with hypercholesterolemia
https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol?utm_campaign=42504259-FnB%2C%20Cosmetics%2C%20Med%20Dev%2C%20Drugs%20%7C%20Newsfeed%20%7C%20Global%20%7C%202026&utm_medium=email&_hsenc=p2ANqtz-_s-MT3cfSv-c6YF_we_1DNE9RTvQBnpwszN5SRJz8BpKuB4iWecy2M79RhPaI1Mq5R-1RIN8NxycqGjB8U3WNBHlXotw&_hsmi=430311558&utm_content=429969268&utm_source=hs_email
FDA Approves First Oral PCSK9 Inhibitor for High Cholesterol
FDA has approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor for adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). Previously available only as injectable therapies, PCSK9 inhibitors now have an oral treatment option that provides significant LDL cholesterol reduction when used alongside diet, exercise, and existing therapies. The approval reflects continued innovation in chronic disease treatment and FDA's commitment to expanding patient access to new therapeutic options.
domingo, 26 de julio de 2026
Engineered probiotic bacteria boost immune attack against pancreatic cancer
https://www.news-medical.net/news/20260724/Engineered-probiotic-bacteria-boost-immune-attack-against-pancreatic-cancer.aspx
Cancer immunotherapies have transformed treatment for many cancers, but pancreatic cancer remains especially difficult to treat. One major reason is that pancreatic tumors often create a "cold" tumor microenvironment, where the tumor prevents immune cells from mounting a strong attack.
Evidence shows artificial sweeteners cannot be judged as a single group
https://www.news-medical.net/news/20260723/Evidence-shows-artificial-sweeteners-cannot-be-judged-as-a-single-group.aspx
A review of seven sweeteners and mixed exposures shows why dose, formulation, diet, and individual biology matter when interpreting their potential effects on the gut and metabolism.
A recent narrative review in the journal Nutrients synthesized the effects of seven individual non-nutritive artificial sweeteners (NASs) and mixed NAS exposures on gut microbiota composition and host metabolic health and developed an interactive knowledge graph to organize and navigate the available evidence.
Our twenty-five year journey The Lancet Infectious Diseases +...
Our twenty-five year journey
The Lancet Infectious Diseases
https://www.thelancet.com/journals/laninf/issue/vol26no8/PIIS1473-3099(26)X2007-2
GLP-1/GIP agonists and cancer: mechanisms, evidence, and nutrition implications Sedat Arslan* [1] , Ayca Aydin [2] + +...
https://www.academia.edu/2998-7741/3/2/10.20935/AcadOnco8234
Obesity and diabetes increase cancer risk through insulin resistance, chronic inflammation, and altered growth signaling. Glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists reshape this metabolic milieu and are increasingly used for weight loss and glycemic control. Uncertainty persists about whether these agents influence cancer incidence or progression, and there is no consensus on nutrition care during therapy. We present a narrative, mechanism-to-clinic review that synthesizes randomized and observational human studies alongside translational evidence on insulin/IGF-1 pathways, adipokines, bile acids, and the microbiota. We also integrate practice-focused guidance on preserving lean mass, monitoring micronutrients, and managing gastrointestinal tolerance while on these agents. Current human evidence does not show a consistent increase in overall cancer risk with these therapies; however, signals are heterogeneous across tumor sites and follow-up remains limited. Randomized trials rarely adjudicate cancer outcomes, and pharmacovigilance and preclinical results are mixed and context-dependent. Weight loss and improved insulin sensitivity plausibly reduce pro-tumorigenic signaling, whereas rapid weight reduction may threaten muscle mass unless accompanied by proactive nutrition support and resistance exercise. Available data suggest no uniform carcinogenic signal from GLP-1/GIP therapies to date, but organ-specific effects and long-term safety require rigorous, adequately powered follow-up. Dietitians and oncology teams should co-manage patients using high-quality protein distributed across meals, fiber-rich, low-glycemic dietary patterns (such as Mediterranean-style eating), resistance exercise, and targeted micronutrient monitoring, alongside standardized recording of cancer-relevant outcomes.
https://www.academia.edu/journals/academia-oncology/articles?source=journal-top-nav
Are Smart Glasses the Future of Collaborative Surgery? Nelly Abulata, MD, PhD, MBA; Amgad Nakhla, MBBCh, PhD + +++++
https://www.medscape.com/viewarticle/are-smart-glasses-future-collaborative-surgery-2026a1000obf?ecd=mkm_ret_260726_mscpmrk-OUS_ExcNews_etid8527949&uac=148436CN&impID=8527949
More Digital Health Pulse Content From This Year
Health Data: Who Owns It, Who Profits, Who Protects It?
https://www.medscape.com/viewarticle/data-new-blood-test-who-owns-it-who-profits-who-protects-it-2026a1000l7l?ecd=mkm_ret_260726_mscpmrk-OUS_ExcNews_etid8527949&uac=148436CN&impID=8527949
Inside OCT and IVUS: AI’s New Edge in PCI
https://www.medscape.com/viewarticle/inside-oct-and-ivus-ais-new-edge-pci-2026a1000fkf?ecd=mkm_ret_260726_mscpmrk-OUS_ExcNews_etid8527949&uac=148436CN&impID=8527949
Can AI Fix the Mental Health Crisis?
https://www.medscape.com/viewarticle/can-ai-fix-mental-health-crisis-2026a1000bcn?ecd=mkm_ret_260726_mscpmrk-OUS_ExcNews_etid8527949&uac=148436CN&impID=8527949
Want Digital Care That Works? Start With These Questions
https://www.medscape.com/viewarticle/want-digital-care-works-start-these-questions-2026a10007oe?ecd=mkm_ret_260726_mscpmrk-OUS_ExcNews_etid8527949&uac=148436CN&impID=8527949
Clinical Practice, Digital Fluency: The Hybrid-Role Era
https://www.medscape.com/viewarticle/clinical-practice-digital-fluency-hybrid-role-era-2026a10005m4?ecd=mkm_ret_260726_mscpmrk-OUS_ExcNews_etid8527949&uac=148436CN&impID=8527949
sábado, 25 de julio de 2026
Winter Break for the "Equitable Health" Blog Group... the blogs will not be updated on July 26, 27, 28, 29, and 30, 2026... We apologize for this, but we hope you understand that we deserve a break... We will return on July 31, God willing... Many thanks to all our readers and followers (whose numbers are constantly growing)... Until then... The Editor...
Receso Invernal del grupo de blog´s de "salud equitativa"... los días 26, 27, 28, 29, y 30 de julio de 2026, los blog´s no se actualizarán... pedimos disculpas por ello, pero esperamos sepan entender que merecemos un descanso... regresaremos el 31 de julio si Dios lo permite... muchas gracias a todos los lectores y seguidores (que cada vez son más)... hasta entonces... El editor...
Grupo de blog´s de “salud equitativa”, cuyo titular es Víctor Norberto Cerasale Morteo, en Salta, Argentina…
https://wwweldispreciau.blogspot.com/
https://eldispensador.blogspot.com/
https://saludequitativa.blogspot.com/
https://herenciageneticayenfermedad.blogspot.com/
https://elbiruniblogspotcom.blogspot.com/
Winter Break for the "Equitable Health" Blog Group... the blogs will not be updated on July 26, 27, 28, 29, and 30, 2026... We apologize for this, but we hope you understand that we deserve a break... We will return on July 31, God willing... Many thanks to all our readers and followers (whose numbers are constantly growing)... Until then... The Editor... "Equitable Health" Blog Group, owned by Víctor Norberto Cerasale Morteo, in Salta, Argentina...
https://wwweldispreciau.blogspot.com/
https://eldispensador.blogspot.com/
https://saludequitativa.blogspot.com/
https://herenciageneticayenfermedad.blogspot.com/
https://elbiruniblogspotcom.blogspot.com/
Pause hivernale pour le groupe de blogs « Equitable Health »… Les articles ne seront pas mis à jour les 26, 27, 28, 29 et 30 juillet 2026… Nous vous prions de nous excuser pour ce désagrément, mais nous espérons que vous comprendrez que nous méritons bien une pause… Nous serons de retour le 31 juillet, si Dieu le veut… Un grand merci à tous nos lecteurs et abonnés (dont le nombre ne cesse de croître)… À bientôt… La rédaction… Le groupe de blogs « Equitable Health », propriété de Víctor Norberto Cerasale Morteo, à Salta, en Argentine…
https://wwweldispreciau.blogspot.com/
https://eldispensador.blogspot.com/
https://saludequitativa.blogspot.com/
https://herenciageneticayenfermedad.blogspot.com/
https://elbiruniblogspotcom.blogspot.com/
Winterpause für die Bloggruppe „Gerechte Gesundheit“ … Die Blogs werden am 26., 27., 28., 29. und 30. Juli 2026 nicht aktualisiert. Wir bitten um Entschuldigung und hoffen auf Ihr Verständnis, dass wir uns eine Auszeit verdient haben. Wir sind am 31. Juli wieder für Sie da, so Gott will. Vielen Dank an alle unsere Leser und Follower (deren Zahl stetig wächst). Bis dahin … Die Redaktion der Bloggruppe „Gerechte Gesundheit“, Inhaber: Víctor Norberto Cerasale Morteo, Salta, Argentinien.
https://wwweldispreciau.blogspot.com/
https://eldispensador.blogspot.com/
https://saludequitativa.blogspot.com/
https://herenciageneticayenfermedad.blogspot.com/
https://elbiruniblogspotcom.blogspot.com/
Зимний перерыв для блог-группы "Equitable Health"... блоги не будут обновляться 26, 27, 28, 29 и 30 июля 2026 года... Приносим свои извинения, но надеемся на ваше понимание, что мы заслужили перерыв... Мы вернемся 31 июля, если Бог даст... Большое спасибо всем нашим читателям и подписчикам (число которых постоянно растет)... До тех пор... Редактор... Блог-группа "Equitable Health", принадлежащая Виктору Норберто Серасале Мортео, Сальта, Аргентина...
https://wwweldispreciau.blogspot.com/
https://eldispensador.blogspot.com/
https://saludequitativa.blogspot.com/
https://herenciageneticayenfermedad.blogspot.com/
https://elbiruniblogspotcom.blogspot.com/
"इक्विटेबल हेल्थ" ब्लॉग ग्रुप के लिए विंटर ब्रेक... ब्लॉग 26, 27, 28, 29, और 30 जुलाई, 2026 को अपडेट नहीं किए जाएंगे... हम इसके लिए माफ़ी चाहते हैं, लेकिन हमें उम्मीद है कि आप समझेंगे कि हम एक ब्रेक के हकदार हैं... हम 31 जुलाई को वापस आएंगे, भगवान चाहेंगे... हमारे सभी रीडर्स और फॉलोअर्स (जिनकी संख्या लगातार बढ़ रही है) का बहुत-बहुत धन्यवाद... तब तक... एडिटर... "इक्विटेबल हेल्थ" ब्लॉग ग्रुप, जिसके मालिक विक्टर नॉरबर्टो सेरासले मोर्टेओ हैं, साल्टा, अर्जेंटीना में है...
https://wwweldispreciau.blogspot.com/
https://eldispensador.blogspot.com/
https://saludequitativa.blogspot.com/
https://herenciageneticayenfermedad.blogspot.com/
https://elbiruniblogspotcom.blogspot.com/
Recesso de Inverno para o Grupo de Blogs "Saúde Equitativa"... os blogs não serão actualizados nos dias 26, 27, 28, 29 e 30 de Julho de 2026... Pedimos desculpa por isso, mas esperamos que compreendam que merecemos uma pausa... Regressaremos no dia 31 de Julho, se Deus quiser... Muito obrigado a todos os nossos leitores e seguidores (cujo número está em constante crescimento)... Até lá... A Equipa Editorial... Grupo de Blogs "Saúde Equitativa", propriedade de Víctor Norberto Cerasale Morteo, em Salta, Argentina...
https://wwweldispreciau.blogspot.com/
https://eldispensador.blogspot.com/
https://saludequitativa.blogspot.com/
https://herenciageneticayenfermedad.blogspot.com/
https://elbiruniblogspotcom.blogspot.com/
Pausa invernale per il gruppo di blog "Equitable Health"... i blog non verranno aggiornati il 26, 27, 28, 29 e 30 luglio 2026... Ci scusiamo per questo, ma speriamo che comprendiate che ci meritiamo una pausa... Torneremo il 31 luglio, a Dio piacendo... Un sentito ringraziamento a tutti i nostri lettori e follower (il cui numero è in costante crescita)... A presto... Il Direttore... Gruppo di blog "Equitable Health", di proprietà di Víctor Norberto Cerasale Morteo, a Salta, Argentina...
https://wwweldispreciau.blogspot.com/
https://eldispensador.blogspot.com/
https://saludequitativa.blogspot.com/
https://herenciageneticayenfermedad.blogspot.com/
https://elbiruniblogspotcom.blogspot.com/
"ஈக்விடபிள் ஹெல்த்" வலைப்பதிவுக் குழுவிற்கு குளிர்கால இடைவேளை... ஜூலை 26, 27, 28, 29, மற்றும் 30, 2026 ஆகிய தேதிகளில் வலைப்பதிவுகள் புதுப்பிக்கப்படாது... இதற்காக வருந்துகிறோம், ஆனால் எங்களுக்கு ஒரு இடைவேளை தேவை என்பதை நீங்கள் புரிந்துகொள்வீர்கள் என்று நம்புகிறோம்... எல்லாம் வல்ல இறைவனின் அருளால், ஜூலை 31 அன்று நாங்கள் திரும்புவோம்... எங்கள் வாசகர்கள் மற்றும் பின்தொடர்பவர்கள் அனைவருக்கும் மிக்க நன்றி (அவர்களின் எண்ணிக்கை தொடர்ந்து அதிகரித்து வருகிறது)... அதுவரை... ஆசிரியர்... "ஈக்விடபிள் ஹெல்த்" வலைப்பதிவுக் குழு, விக்டர் நோர்பெர்டோ செராசேல் மோர்டியோவுக்குச் சொந்தமானது, சால்டா, அர்ஜென்டினா...
https://wwweldispreciau.blogspot.com/
https://eldispensador.blogspot.com/
https://saludequitativa.blogspot.com/
https://herenciageneticayenfermedad.blogspot.com/
https://elbiruniblogspotcom.blogspot.com/
“公平健康”博客组冬季休刊……博客将于2026年7月26日、27日、28日、29日和30日暂停更新……对此我们深表歉意，但希望您能理解我们需要休息……我们将于7月31日恢复更新，如果一切顺利……非常感谢所有读者和关注者（人数还在不断增长）……此致……编辑……“公平健康”博客组，由阿根廷萨尔塔省的维克托·诺贝托·塞拉萨莱·莫特奥所有……
https://wwweldispreciau.blogspot.com/
https://eldispensador.blogspot.com/
https://saludequitativa.blogspot.com/
https://herenciageneticayenfermedad.blogspot.com/
https://elbiruniblogspotcom.blogspot.com/
Who owns cardiometabolic disease? The Lancet +... + +
Who owns cardiometabolic disease?
The Lancet
https://www.thelancet.com/journals/lancet/issue/vol408no10552/PIIS0140-6736(26)X2027-X
Who owns cardiometabolic disease?
The Lancet
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01497-2/fulltext?dgcid=raven_jbs_etoc_feature_lancet
Towards precision medicine: electroconvulsive therapy as a treatment option in a rare disease
Dr Jana de Villiers, FRCPsycha Send email to jana.devilliers@nhs.scot ∙ Prof Jennifer Mulle, PhDb ∙ Sujatha Maiya, MRCPsychc ∙ Adannaya Igwe, MBBChir
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00694-X/abstract?dgcid=raven_jbs_etoc_feature_lancet
Naming disease, shaping care: patient perspectives matter eClinicalMedicine ++... +
Naming disease, shaping care: patient perspectives matter
eClinicalMedicine
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00378-0/fulltext?dgcid=raven_jbs_etoc_email
Jul 2026
Volume 97
https://www.thelancet.com/journals/eclinm/issue/vol97nonull/PIIS2589-5370(26)X2007-7
Challenges and possible solutions towards reaching global cervical cancer elimination
Laila Sara Arroyo Mühr ∙ Joakim Dillner
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00138-0/fulltext?dgcid=raven_jbs_etoc_feature_eclinm
Drinking Water Contaminants Tied to Uterine Cancer Risk Megan Brooks July 24, 2026 JAMA Netw Open. 2026;9(7):e2624391. doi:10.1001/jamanetworkopen.2026.24391
https://www.medscape.com/viewarticle/drinking-water-contaminants-tied-uterine-cancer-risk-2026a1000p62?src=
Women with relatively greater exposure to common disinfection byproducts in drinking water — even at levels below federal limits — may be at an increased risk for uterine cancer, a large prospective study suggests.
Among over 53,000 California women followed for two decades, those exposed to the highest levels of disinfection byproducts called trihalomethanes (THMs) had an 18% higher risk for uterine cancer vs women with the lowest exposure levels. They also had a 23% higher risk for endometrioid tumors, specifically.
MRI-Based Staging Matches Digital Rectal Examination Accuracy in Prostate Cancer Survival Edited by Mamta Pawara
https://www.medscape.com/viewarticle/mri-based-staging-matches-digital-rectal-examination-2026a1000omm?src=
Preoperative MRI-based T staging demonstrated oncologic risk discrimination comparable to traditional digital rectal examinations (DREs) for predicting survival outcomes in men with clinically localised or locally advanced prostate cancer (PCa) who underwent radical prostatectomy, a multicentre study found.
Stem Cell Transplant Associated With Better PFS in Natural Killer/T-Cell Lymphoma Edited by Katie Lennon July 24, 2026 Am J Hematol. 2026; doi:10.1002/ajh.70415
https://www.medscape.com/viewarticle/stem-cell-transplant-associated-better-pfs-natural-killer-t-2026a1000p7b?src=
Upfront autologous stem cell transplantation (ASCT) consolidation is associated with improved progression-free survival (PFS) in patients with advanced-stage extranodal natural killer/T-cell lymphoma (NKTCL) who achieve a first complete remission after frontline therapy. Among 107 patients studied, those receiving ASCT had a 3-year PFS rate of 78.2% compared with 54.6% in the non-ASCT group.
For Kids, Survival of LC Histiocytosis Now Achieved in All But Most Severe Cases Ted Bosworth
https://www.medscape.com/viewarticle/kids-survival-lc-histiocytosis-now-achieved-all-most-severe-2026a1000p8r?src=
MINNEAPOLIS — Many forms of histiocytoses in children are skin-limited and relatively benign, but fatalities related to Langerhans cell histiocytosis (LCH), a relatively severe form, are increasingly uncommon unless high-risk organs are affected, according to a global expert.
Radiation Deserts Grow as Rural Radiation Sites Are Lost, Threatening Access Megan Brooks
https://www.medscape.com/viewarticle/radiation-deserts-grow-rural-radiation-sites-are-lost-2026a1000p5s
More than two thirds of US counties — home to over 50 million people — lacked a radiation oncology practice site in 2025, according to a national analysis of Medicare data. The analysis also found that, between 2018 and 2025, freestanding (community-based) radiation oncology practice sites had higher odds of disappearing than hospital-affiliated sites, whereas practice sites in rural counties had higher odds of disappearing than those in urban counties.
Smoldering Myeloma: The Treatment Issue Is Getting Trickier David Brzostowicki
https://www.medscape.com/viewarticle/smoldering-myeloma-treatment-issue-getting-trickier-2026a1000p2y
The landscape around high-risk smoldering multiple myeloma has been shifting quickly in the past year. Last November, the FDA approved the monoclonal antibody daratumumab (Darzalex Faspro) based on the phase 3 AQUILA trial, which showed the drug delayed progression compared with active monitoring. Since then, early-phase trials of CAR T-cell therapy and bispecific antibodies have reported deep remissions in the smoldering setting — with some investigators raising the possibility of a cure.
RARE Round-up - keeping you up-to-date
https://editions.rarerevolutionmagazine.com/html5/reader/production/default.aspx?pubname=&edid=e0508b93-1cde-4785-b9ae-c36724bde55a&pnum=36
Global umbrella organisations are often expected to “speak for everyone”. However, the challenge of being a universal voice is not insignificant when representing communities that span geographical borders, political and cultural contexts and can vary from infrastructure that includes advanced gene therapy centres in Europe contrasted with families lacking access to the most basic wound dressings in rural Asia. In conversation with DEBRA International, president Dr Ritu Jain, we explore what it really means to lead across this equity chasm, the hidden ethics of “global” solutions and why listening to lived priorities must come before policy wins
Notable Approval: FDA Approves First Nonprescription Fixed-Dose Combination of Acetaminophen and Naproxen Sodium for 12-Hour Pain Relief
Notable Approval: FDA Approves First Nonprescription Fixed-Dose Combination of Acetaminophen and Naproxen Sodium for 12-Hour Pain Relief
On July 24, FDA approved Tylenol with Naproxen (acetaminophen 325 mg/naproxen sodium 110 mg tablets), the first fixed-dose combination product to pair acetaminophen with naproxen sodium in a single combination tablet for up to 12 hours of pain relief. This nonprescription product is indicated for the temporary relief of minor aches and pains due to headache, backache, muscular aches, toothache, menstrual cramps, and minor pain of arthritis in adults and children 12 years and older.
This action aligns with President Trump’s The Great Healthcare Plan, a federal effort to make more verified safe pharmaceutical drugs available for over-the-counter purchase. This will lower healthcare costs and increase consumer choice by strengthening price transparency, increasing competition, and reducing the need for costly and time-consuming doctor’s visits.
Condition
Minor aches and pains are some of the most common reasons Americans reach for a nonprescription (or, over-the-counter, OTC) medication. Acetaminophen and naproxen sodium are among the most widely used OTC pain relievers in the United States, each with decades of established use and well-characterized safety profiles. Together in a single tablet, the two active ingredients are combined to provide consumers with a new nonprescription option for up to 12 hours of pain relief. While other combination acetaminophen and nonsteroidal anti-inflammatory drug (NSAID) products currently exist on the market, this is the first product to combine naproxen sodium with acetaminophen.
Data Supporting Tylenol with Naproxen
The approval was supported by evidence establishing the effectiveness and safety of the combination drug and demonstrating the contribution of each ingredient to the overall pain relief effect of the combination. Tylenol with Naproxen is dosed every 12 hours. The labeling for Tylenol with Naproxen is consistent with other nonprescription products in its class and includes standard warnings applicable to both acetaminophen- and NSAID-containing products.
Safety Information
As with all acetaminophen-containing products, consumers are warned not to use Tylenol with Naproxen with other drugs containing acetaminophen, as doing so may cause liver damage. As with all NSAID-containing products, the labeling includes warnings for stomach bleeding and for increased risk of heart attack, heart failure, and stroke — risks that are higher when NSAIDs are used more than directed or for longer than directed.
The labeling for Tylenol with Naproxen includes pregnancy-related recommendations consistent with all other acetaminophen- or NSAID-containing nonprescription products. Specifically, the label advises that those who are pregnant or breast-feeding ask a health professional before use. Also, the Drug Facts label indicates it is important not to use naproxen sodium at 20 weeks or later in pregnancy unless definitely directed to do so by a doctor.
FDA encourages all consumers to read and follow the labeling carefully and to consult a healthcare provider if they have unanswered questions.
Tylenol with Naproxen is manufactured by Kenvue Brands LLC.
https://www.whitehouse.gov/greathealthcare/?utm_medium=email&utm_source=govdelivery
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219962Orig1s000Lbl.pdf?utm_medium=email&utm_source=govdelivery
viernes, 24 de julio de 2026
Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks by Madaline Spencer| Published on: Jun 25, 2026
https://checkrare.com/oral-deucrictibant-for-on-demand-treatment-of-hereditary-angioedema-attacks/
Receso Invernal del grupo de blog´s de "salud equitativa"... los días 26, 27, 28, 29, y 30 de julio de 2026, los blog´s no se actualizarán... pedimos disculpas por ello, pero esperamos sepan entender que merecemos un descanso... regresaremos el 31 de julio si Dios lo permite... muchas gracias a todos los lectores y seguidores (que cada vez son más)... hasta entonces... El editor...
Grupo de blog´s de “salud equitativa”, cuyo titular es Víctor Norberto Cerasale Morteo, en Salta, Argentina…
https://wwweldispreciau.blogspot.com/
https://eldispensador.blogspot.com/
https://saludequitativa.blogspot.com/
https://herenciageneticayenfermedad.blogspot.com/
https://elbiruniblogspotcom.blogspot.com/
Winter Break for the "Equitable Health" Blog Group... the blogs will not be updated on July 26, 27, 28, 29, and 30, 2026... We apologize for this, but we hope you understand that we deserve a break... We will return on July 31, God willing... Many thanks to all our readers and followers (whose numbers are constantly growing)... Until then... The Editor... "Equitable Health" Blog Group, owned by Víctor Norberto Cerasale Morteo, in Salta, Argentina...
https://wwweldispreciau.blogspot.com/
https://eldispensador.blogspot.com/
https://saludequitativa.blogspot.com/
https://herenciageneticayenfermedad.blogspot.com/
https://elbiruniblogspotcom.blogspot.com/
Pause hivernale pour le groupe de blogs « Equitable Health »… Les articles ne seront pas mis à jour les 26, 27, 28, 29 et 30 juillet 2026… Nous vous prions de nous excuser pour ce désagrément, mais nous espérons que vous comprendrez que nous méritons bien une pause… Nous serons de retour le 31 juillet, si Dieu le veut… Un grand merci à tous nos lecteurs et abonnés (dont le nombre ne cesse de croître)… À bientôt… La rédaction… Le groupe de blogs « Equitable Health », propriété de Víctor Norberto Cerasale Morteo, à Salta, en Argentine…
https://wwweldispreciau.blogspot.com/
https://eldispensador.blogspot.com/
https://saludequitativa.blogspot.com/
https://herenciageneticayenfermedad.blogspot.com/
https://elbiruniblogspotcom.blogspot.com/
Winterpause für die Bloggruppe „Gerechte Gesundheit“ … Die Blogs werden am 26., 27., 28., 29. und 30. Juli 2026 nicht aktualisiert. Wir bitten um Entschuldigung und hoffen auf Ihr Verständnis, dass wir uns eine Auszeit verdient haben. Wir sind am 31. Juli wieder für Sie da, so Gott will. Vielen Dank an alle unsere Leser und Follower (deren Zahl stetig wächst). Bis dahin … Die Redaktion der Bloggruppe „Gerechte Gesundheit“, Inhaber: Víctor Norberto Cerasale Morteo, Salta, Argentinien.
https://wwweldispreciau.blogspot.com/
https://eldispensador.blogspot.com/
https://saludequitativa.blogspot.com/
https://herenciageneticayenfermedad.blogspot.com/
https://elbiruniblogspotcom.blogspot.com/
Зимний перерыв для блог-группы "Equitable Health"... блоги не будут обновляться 26, 27, 28, 29 и 30 июля 2026 года... Приносим свои извинения, но надеемся на ваше понимание, что мы заслужили перерыв... Мы вернемся 31 июля, если Бог даст... Большое спасибо всем нашим читателям и подписчикам (число которых постоянно растет)... До тех пор... Редактор... Блог-группа "Equitable Health", принадлежащая Виктору Норберто Серасале Мортео, Сальта, Аргентина...
https://wwweldispreciau.blogspot.com/
https://eldispensador.blogspot.com/
https://saludequitativa.blogspot.com/
https://herenciageneticayenfermedad.blogspot.com/
https://elbiruniblogspotcom.blogspot.com/
"इक्विटेबल हेल्थ" ब्लॉग ग्रुप के लिए विंटर ब्रेक... ब्लॉग 26, 27, 28, 29, और 30 जुलाई, 2026 को अपडेट नहीं किए जाएंगे... हम इसके लिए माफ़ी चाहते हैं, लेकिन हमें उम्मीद है कि आप समझेंगे कि हम एक ब्रेक के हकदार हैं... हम 31 जुलाई को वापस आएंगे, भगवान चाहेंगे... हमारे सभी रीडर्स और फॉलोअर्स (जिनकी संख्या लगातार बढ़ रही है) का बहुत-बहुत धन्यवाद... तब तक... एडिटर... "इक्विटेबल हेल्थ" ब्लॉग ग्रुप, जिसके मालिक विक्टर नॉरबर्टो सेरासले मोर्टेओ हैं, साल्टा, अर्जेंटीना में है...
https://wwweldispreciau.blogspot.com/
https://eldispensador.blogspot.com/
https://saludequitativa.blogspot.com/
https://herenciageneticayenfermedad.blogspot.com/
https://elbiruniblogspotcom.blogspot.com/
Recesso de Inverno para o Grupo de Blogs "Saúde Equitativa"... os blogs não serão actualizados nos dias 26, 27, 28, 29 e 30 de Julho de 2026... Pedimos desculpa por isso, mas esperamos que compreendam que merecemos uma pausa... Regressaremos no dia 31 de Julho, se Deus quiser... Muito obrigado a todos os nossos leitores e seguidores (cujo número está em constante crescimento)... Até lá... A Equipa Editorial... Grupo de Blogs "Saúde Equitativa", propriedade de Víctor Norberto Cerasale Morteo, em Salta, Argentina...
https://wwweldispreciau.blogspot.com/
https://eldispensador.blogspot.com/
https://saludequitativa.blogspot.com/
https://herenciageneticayenfermedad.blogspot.com/
https://elbiruniblogspotcom.blogspot.com/
Pausa invernale per il gruppo di blog "Equitable Health"... i blog non verranno aggiornati il 26, 27, 28, 29 e 30 luglio 2026... Ci scusiamo per questo, ma speriamo che comprendiate che ci meritiamo una pausa... Torneremo il 31 luglio, a Dio piacendo... Un sentito ringraziamento a tutti i nostri lettori e follower (il cui numero è in costante crescita)... A presto... Il Direttore... Gruppo di blog "Equitable Health", di proprietà di Víctor Norberto Cerasale Morteo, a Salta, Argentina...
https://wwweldispreciau.blogspot.com/
https://eldispensador.blogspot.com/
https://saludequitativa.blogspot.com/
https://herenciageneticayenfermedad.blogspot.com/
https://elbiruniblogspotcom.blogspot.com/
"ஈக்விடபிள் ஹெல்த்" வலைப்பதிவுக் குழுவிற்கு குளிர்கால இடைவேளை... ஜூலை 26, 27, 28, 29, மற்றும் 30, 2026 ஆகிய தேதிகளில் வலைப்பதிவுகள் புதுப்பிக்கப்படாது... இதற்காக வருந்துகிறோம், ஆனால் எங்களுக்கு ஒரு இடைவேளை தேவை என்பதை நீங்கள் புரிந்துகொள்வீர்கள் என்று நம்புகிறோம்... எல்லாம் வல்ல இறைவனின் அருளால், ஜூலை 31 அன்று நாங்கள் திரும்புவோம்... எங்கள் வாசகர்கள் மற்றும் பின்தொடர்பவர்கள் அனைவருக்கும் மிக்க நன்றி (அவர்களின் எண்ணிக்கை தொடர்ந்து அதிகரித்து வருகிறது)... அதுவரை... ஆசிரியர்... "ஈக்விடபிள் ஹெல்த்" வலைப்பதிவுக் குழு, விக்டர் நோர்பெர்டோ செராசேல் மோர்டியோவுக்குச் சொந்தமானது, சால்டா, அர்ஜென்டினா...
https://wwweldispreciau.blogspot.com/
https://eldispensador.blogspot.com/
https://saludequitativa.blogspot.com/
https://herenciageneticayenfermedad.blogspot.com/
https://elbiruniblogspotcom.blogspot.com/
“公平健康”博客组冬季休刊……博客将于2026年7月26日、27日、28日、29日和30日暂停更新……对此我们深表歉意，但希望您能理解我们需要休息……我们将于7月31日恢复更新，如果一切顺利……非常感谢所有读者和关注者（人数还在不断增长）……此致……编辑……“公平健康”博客组，由阿根廷萨尔塔省的维克托·诺贝托·塞拉萨莱·莫特奥所有……
https://wwweldispreciau.blogspot.com/
https://eldispensador.blogspot.com/
https://saludequitativa.blogspot.com/
https://herenciageneticayenfermedad.blogspot.com/
https://elbiruniblogspotcom.blogspot.com/
DAHLIAS Clinical Trial Evaluating Nipocalimab in Sjögren’s Disease by Madaline Spencer| Published on: Jul 23, 2026
DAHLIAS Clinical Trial Evaluating Nipocalimab in Sjögren’s Disease
by Madaline Spencer| Published on: Jul 23, 2026
Robert Hal Scofield, MD, Professor of Medicine, at the University of Oklahoma and Oklahoma Medical Research Foundation, discusses the DAHLIAS clinical trial evaluating nipocalimab in Sjögren’s disease (SjD).
https://checkrare.com/dahlias-clinical-trial-evaluating-nipocalimab-in-sjogrens-disease/
Investigating Results From the MAVORIC Trial in Patients With CTCL by CheckRare Staff| Published on: Jul 24, 2026
Investigating Results From the MAVORIC Trial in Patients With CTCL
by CheckRare Staff| Published on: Jul 24, 2026
H. Miles Prince, MD, MBBS, Professor at the University of Melbourne, Australia, and Director, Peter MacCallum Cancer Center, and Director of Molecular Oncology and Cancer Immunology, Epworth HealthCare, describes the objectives and results of a new investigation which studied the previous results from the MAVORIC trial in patients with cutaneous T-cell lymphoma with those of patients in an Australian cancer registry.
https://checkrare.com/investigating-results-from-the-mavoric-trial-in-patients-with-ctcl/
The Gen-Z Credit Trap By Ivanhoe Broadcast News on July 27, 2026
Orlando, Fla. (Ivanhoe Newswire) — More young adults are entering adulthood already in debt. The average gen z credit card balance is about 35 hundred dollars. For millennials it’s nearly seven thousand. At the same time, nearly half of Gen Z admits they don’t fully understand how credit scores work. That can be costly because one bad money move can get expensive fast.
https://www.ivanhoe.com/?p=37377&preview=1&_ppp=1d53c2357d
Beating AI Anxiety On The Job By Ivanhoe Broadcast News on July 28, 2026
Orlando, Fla. (Ivanhoe Newswire) — It’s a new era in the workplace. Gallup reports nearly four in 10 employees say their organization has already adopted AI tools. And with that shift comes a new kind of stress, fear of being replaced. But experts say panic isn’t the answer.
https://www.ivanhoe.com/?p=37380&preview=1&_ppp=86b0f6b8e2
Planting Purpose & Cultivating Connection By Ivanhoe Broadcast News on July 29, 2025
ORLANDO, Fla. (Ivanhoe Newswire) — In a time when parents are looking for ways to help their children build resilience — some young people are turning to the roots, literally. Studies show that spending time outdoors and participating in community-based solutions can ease stress and reduce anxiety in youth and young adults, especially as they face a world filled with uncertainty.
https://www.ivanhoe.com/positive-parenting/planting-purpose-cultivating-connection/
When Heat Turns Deadly: What Parents Need to Know By Ivanhoe Broadcast News on July 30, 2025
GAINESVILLE, Fla. (Ivanhoe Newswire) — The summer heat is on and it’s getting hotter and deadlier. Kids are among the most vulnerable. From the playground to football practice, extreme temperatures can turn dangerous — fast.
https://www.ivanhoe.com/positive-parenting/when-heat-turns-deadly-what-parents-need-to-know/
IDEAS For Us: Eco-Action Empowering People By Ivanhoe Broadcast News on July 31, 2025
ORLANDO, Fla. (Ivanhoe Newswire) — Raising environmentally responsible kids isn’t just about recycling — it’s about results. A global movement that started by two college kids is now teaching children around the world to take real eco-action, from growing food to planting trees.
https://www.ivanhoe.com/positive-parenting/ideas-for-us-eco-action-empowering-people/
Can virtual patients predict whether a drug will succeed? Written byBree Foster, PhD +++
Can virtual patients predict whether a drug will succeed?
Phase Advance is using mechanistic virtual patient models to predict how LEAF4Life's hypoxia-targeting therapy could perform across multiple indications.
Written byBree Foster, PhD
https://www.drugdiscoverynews.com/can-virtual-patients-predict-whether-a-drug-will-succeed-17347
Even after years of laboratory research and early clinical testing, most drug candidates fail before reaching patients. Recent advances in AI and computational drug development have yet to change that reality, with the percentage of Phase 2 and 3 trials terminated before completion more than doubling from 11 percent to 23 percent between 2013 and 2023.
Can the healthcare system catch up to GLP-1 drug use?
Millions of patients are now taking drugs like Ozempic and Wegovy, but clinicians still struggle to predict who will benefit and how best to support lasting results.
Written byBree Foster, PhD
https://www.drugdiscoverynews.com/can-the-healthcare-system-catch-up-to-glp-1-drug-use-17108?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-87M9M94gCRS1KWaKwRDSCAJjCZAQeHu4xpb8jM0y9ySGgXaZd3n_-xqrcrkMPG1MnpPkZ-xqhyk3wDX3QUpM5p3l5TPg&_hsmi=429953149&utm_content=429953149&utm_source=hs_email
When GLP-1 drugs first entered clinical practice nearly two decades ago, few could have predicted how quickly they would escape the confines of endocrinology and enter everyday conversation. Today, medications like Ozempic and Wegovy are discussed not just in clinics and conferences, but on social media, red carpets, and group chats — often framed as lifestyle enhancers rather than powerful, lifelong medications.
Gut microbes help turn white fat into calorie-burning beige fat
A new study shows how specific gut bacteria work with diet to trigger fat browning in mice, revealing potential pathways for future metabolic therapies.
Written byBree Foster, PhD
https://www.drugdiscoverynews.com/gut-microbes-help-turn-white-fat-into-calorie-burning-beige-fat-17065?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8fggwWOrC4Br-U4br8pECNBbLe9tudzekwHjhWVmg4tkW-3xYyOmQkAp88uNb5avmO48BZZa9UvVd-fAMsYQ-ps2YxbQ&_hsmi=429953149&utm_content=429953149&utm_source=hs_email
When we think about fat, we most often imagine white fat cells, which store excess calories like tiny batteries, providing insulation and cushioning for muscles, bones, and organs. But not all fat is built to store energy. Brown fat does the opposite, burning calories to generate heat and keep the body warm. And then there is beige fat. First identified in 2008, beige fat resides within white fat tissue but functions like brown fat, efficiently burning energy when the body is exposed to cold.
Lilly's triple agonist just became its most powerful obesity drug yet Positive results in metabolic disease, a possible vaccine to treat the current Ebola outbreak, new cancer drug targets, and more led the news this week. Written byDDN editorial team
https://www.drugdiscoverynews.com/lilly-s-triple-agonist-just-became-its-most-powerful-obesity-drug-yet-17377?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_8UNGs9XnQMeGP67zJ9wcnTEbfLetfH5DlguUl4JrT3b9BXyXaeMU9GKOZfJ6oJ6LF16FyVsWvVIyzr_8spCQgDS3UIg&_hsmi=429953149&utm_content=429953149&utm_source=hs_email
Lilly's triple agonist retatrutide posts its strongest weight loss numbers yet, setting up a 2027 FDA filing
Eli Lilly, this week, reported positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials of retatrutide, a once-weekly injectable that activates receptors for GIP, GLP-1, and glucagon simultaneously — a triple mechanism that no approved obesity therapy currently matches. In TRIUMPH-2, adults with obesity and type 2 diabetes lost up to an average of 49.6 pounds, or 20.8 percent of body weight, at 80 weeks on the highest 12mg dose, with A1C dropping by an average of 1.5 percent. In TRIUMPH-3, adults with severe obesity and established cardiovascular disease lost up to an average of 55.8 pounds, or 22.6 percent. Cardiovascular event data from TRIUMPH-3 trended favorably but the trial was not powered to draw conclusions on that endpoint. The drug also produced notable reductions in triglycerides, non-HDL cholesterol, systolic blood pressure, and the inflammatory marker hsCRP. Lilly plans to file a Biologics License Application with the FDA in Q1 2027, with the same data package supporting additional submissions for knee osteoarthritis pain and obstructive sleep apnea. Five consecutive positive Phase 3 readouts across the TRIUMPH program now give Lilly a credible path to fielding three distinct obesity medicines at once. – Andrea Corona
Oncology Perspective +++ +...
Oncology Perspective
Liberalized Diet Fails to Match Neutropenic Safety
Dr Maurie Markman discusses why modifying cancer diets without RCT data poses major risks, highlighting a trial halted due to a 10% spike in serious infections.
Medscape Oncology, July 23, 2026
https://www.medscape.com/viewarticle/liberalized-diet-fails-match-neutropenic-safety-2026a1000n3r
Carl H. June on CAR-T’s Next Frontier: Autoimmune Disease
In an interview, Carl H. June discusses how CAR-T therapy transformed blood cancer treatment, the challenges of extending it to solid tumors, and why autoimmune disease may be its next major frontier.
Medscape Global, July 23, 2026
https://www.medscape.com/viewarticle/carl-h-june-car-ts-next-frontier-autoimmune-disease-2026a1000ozk
What Fellowship Didn’t Teach Us About Loss
What happens when an oncologist loses a patient? Dr Bishal Gyawali talks about normalizing grief in medicine and the power of that final call to the family.
Medscape Oncology, July 22, 2026
https://www.medscape.com/viewarticle/most-important-call-what-fellowship-didnt-teach-us-about-2026a1000ojb
A Blood Test for Colon Cancer Screening? Not So Fast!
Dr Aasma Shaukat says that the convenience of a blood test for colorectal cancer should not outweigh the performance of a blood test, especially when weighed against the other options available.
https://www.medscape.com/index/list_13293_0
MHRA Contraindicates Domperidone in Phaeochromocytoma Dr Sheena Meredith
https://www.medscape.com/viewarticle/mhra-contraindicates-domperidone-phaeochromocytoma-2026a1000otk?src=
Domperidone is now contraindicated in patients with confirmed or suspected phaeochromocytoma because of the risk of severe hypertension, the Medicines and Healthcare products Regulatory Agency (MHRA) has said in a new drug safety update. The update follows a European review of domperidone safety data that identified four reports of severe hypertension in these patients.
MRI-Based Staging Matches Digital Rectal Examination Accuracy in Prostate Cancer Survival Edited by Mamta Pawara
https://www.medscape.com/viewarticle/mri-based-staging-matches-digital-rectal-examination-2026a1000omm?src=
Preoperative MRI-based T staging demonstrated oncologic risk discrimination comparable to traditional digital rectal examinations (DREs) for predicting survival outcomes in men with clinically localised or locally advanced prostate cancer (PCa) who underwent radical prostatectomy, a multicentre study found.
Stem Cell Transplant Associated With Better PFS in Natural Killer/T-Cell Lymphoma Edited by Katie Lennon July 24, 2026 Am J Hematol. 2026; doi:10.1002/ajh.70415
https://www.medscape.com/viewarticle/stem-cell-transplant-associated-better-pfs-natural-killer-t-2026a1000p7b?src=
Upfront autologous stem cell transplantation (ASCT) consolidation is associated with improved progression-free survival (PFS) in patients with advanced-stage extranodal natural killer/T-cell lymphoma (NKTCL) who achieve a first complete remission after frontline therapy. Among 107 patients studied, those receiving ASCT had a 3-year PFS rate of 78.2% compared with 54.6% in the non-ASCT group.
Oncology News +++ ++ +...
Oncology News
Stem Cell Transplant Associated With Better PFS in NKTCL
Researchers aim to evaluate the effectiveness of ASCT as consolidation therapy for patients with advanced-stage natural killer/T-cell lymphoma who have attained their first complete remission.
Medscape Medical News, July 24, 2026
https://www.medscape.com/viewarticle/stem-cell-transplant-associated-better-pfs-natural-killer-t-2026a1000p7b
Drinking Water Contaminants Tied to Uterine Cancer Risk
A large study links long-term exposure to disinfection byproducts in drinking water to uterine cancer, but experts stress the limitations of the data.
Medscape Medical News, July 24, 2026
https://www.medscape.com/viewarticle/drinking-water-contaminants-tied-uterine-cancer-risk-2026a1000p62
Radiation Deserts Grow as Rural Radiation Sites Are Lost
More than 50 million Americans live in counties without a radiation oncology practice site as rural and community-based centers disappear at higher rates.
Medscape Medical News, July 24, 2026
https://www.medscape.com/viewarticle/radiation-deserts-grow-rural-radiation-sites-are-lost-2026a1000p5s
MRI Staging Matches DRE Accuracy in Prostate Cancer Survival
A multicentre study shows that MRI-based local T staging provides risk discrimination similar to digital rectal examinations for clinically localised or locally advanced prostate cancer.
Medscape News UK, July 24, 2026
https://www.medscape.com/viewarticle/mri-based-staging-matches-digital-rectal-examination-2026a1000omm
Glioma Outcomes Shaped by Subtype More Than Tx Sequence
In high-risk low-grade glioma, starting with temozolomide or radiotherapy yields similar survival.
Medscape Medical News, July 24, 2026
https://www.medscape.com/viewarticle/glioma-outcomes-shaped-subtype-more-than-treatment-sequence-2026a1000p3z
Smoldering Myeloma: The Treatment Issue Is Getting Trickier
An FDA approval, striking CAR T data, and a field that can't agree on what to do next. Experts weigh in on the most contentious question in myeloma.
Medscape Medical News, July 23, 2026
https://www.medscape.com/index/list_13474_0
Younger Than 50 Years: New Research Reveals Trends Damian McNamara, MA July 23, 2026
https://www.medscape.com/viewarticle/colorectal-cancer-screening-adults-younger-than-50-years-new-2026a1000oxg?ecd=WNL_trdalrt_pos1_ous_260724_etid8534150&uac=148436CN&impID=8534150
The proportion of Americans younger than 50 years getting screened for colorectal cancer has increased in the past 5 years since guidelines lowered the minimum age to 45 years. However, not all gains have been equitable, with screening rates varying by race/ethnicity, income, and age in two recent studies that examined the success of the recommendations for expanding screening.
jueves, 23 de julio de 2026
Short-term immunosuppressive therapy briefly restores autism-like brain changes in adult mice
https://www.news-medical.net/news/20260723/Short-term-immunosuppressive-therapy-briefly-restores-autism-like-brain-changes-in-adult-mice.aspx
A new mouse study led by UCLA Health suggests that inflammation during pregnancy can trigger autism-like changes in offspring, but also that those brain and behavior effects may be rapidly but temporarily reversible in adulthood with a short-term dose of the immunosuppressive drug rapamycin.
Study reveals unexpected mechanism driving extreme antibiotic resistance
https://www.news-medical.net/news/20260723/Study-reveals-unexpected-mechanism-driving-extreme-antibiotic-resistance.aspx
A patient with a severe infection is prescribed a potent antibiotic. Hopes for improvement are high, but just after treatment is given, resistance to the drug increases thousands of times. How could this happen?
Stuffed toys can release short-chain PFAS into saliva, study finds
https://www.news-medical.net/news/20260722/Stuffed-toys-can-release-short-chain-PFAS-into-saliva-study-finds.aspx
A saliva-based test shows how plush toys may add to young children’s PFAS exposure, while revealing why a simple rinse is not a guaranteed solution.
Can virtual patients predict whether a drug will succeed? Phase Advance is using mechanistic virtual patient models to predict how LEAF4Life's hypoxia-targeting therapy could perform across multiple indications. Written byBree Foster, PhD
Can virtual patients predict whether a drug will succeed?
Phase Advance is using mechanistic virtual patient models to predict how LEAF4Life's hypoxia-targeting therapy could perform across multiple indications.
Written byBree Foster, PhD
https://www.drugdiscoverynews.com/can-virtual-patients-predict-whether-a-drug-will-succeed-17347?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8s57svN6Mo4YAkrHnHI5ITZbWDJs8HiJRiXUti_32xUw9yxJ5T6K6Smz82PyyP_hDHSN41_C-SqslS1_xw0tAxA9QQ9A&_hsmi=429665426&utm_content=429665426&utm_source=hs_email
Science Literacy Project Daily Digest ++++ +
Is the longevity obsession a new form of ageism?
Theresa MacPhail | The Guardian
https://geneticliteracyproject.org/2026/07/23/is-the-longevity-obsession-a-new-form-of-ageism/
Viewpoint: Kratom ‘supplement’ crisis: DEA sits on its hands while patient addictions to this ineffective drug rise
Andrew Kolodny | Washington Post
https://geneticliteracyproject.org/2026/07/23/viewpoint-kratom-supplement-crisis-dea-sits-on-its-hands-while-patient-addictions-to-this-ineffective-drug-rise/
High cholesterol? FDA approves effective oral medication
Food and Drug Administration
https://geneticliteracyproject.org/2026/07/23/high-cholesterol-fda-approves-effective-oral-medication/
Regulating cultured meat around the world
Deniz Ataman | Food Navigator
https://geneticliteracyproject.org/2026/07/22/regulating-cultured-meat-around-the-world/
The Indian physician’s one-woman battle against health disinformation on Wikipedia
Laasya Shekhar | The Xylom
https://geneticliteracyproject.org/2026/07/22/the-indian-physicians-one-woman-battle-against-health-disinformation-on-wikipedia/
For over a decade, Dr. Netha Hussain has been part of the last line of defense against public health disinformation on Wikipedia, the free online encyclopedia.
‘Explosive diarrhoea’ outbreak grips US: how researchers are hunting its source Cases have hit record levels, and scientists are racing to pinpoint where the Cyclospora parasite entered the food supply. By Max Kozlov
https://www.nature.com/articles/d41586-026-02225-w?utm_source=Live+Audience&utm_campaign=69935b4cfc-nature-briefing-daily-20260716&utm_medium=email&utm_term=0_-33f35e09ea-50432164
Scientists hunt Cyclospora source
Health officials in the United States are racing to pin down the origins of a widespread outbreak of the diarrhoeal disease cyclosporiasis. The parasite that causes the disease, Cyclospora cayetanensis, is difficult to trace because there’s a delay between consuming contaminated food and the appearance of symptoms, researchers say. The efforts are also complicated by cuts to health agencies made by the US government. “The number of staff working on these outbreaks is not what it used to be”, says Joel Barratt, former leader of the parasite surveillance team at the US Centers for Disease Control and Prevention.
Biologists pinpoint how common virus triggers multiple sclerosis A connection with Epstein–Barr virus has long been suspected, but the underlying mechanism was unclear until now. By Rachel Fieldhouse
https://www.nature.com/articles/d41586-026-02204-1?utm_source=Live+Audience&utm_campaign=69935b4cfc-nature-briefing-daily-20260716&utm_medium=email&utm_term=0_-33f35e09ea-50432164
T-cell overdrive links virus to MS
Epstein-Barr virus (EBV) triggers a particularly strong immune response from a particular type of T cell, which hints at why the virus is implicated in the development of the autoimmune disorder multiple sclerosis (MS). Researchers found that the activity of CD4+ T cells in response to EBV was twice as high in people with MS compared to people without the condition, but responsiveness decreased markedly when CD4+ cells were depleted. A treatment that depletes B cells, the immune cells that EBV infects, also reduced CD4+ response, because the cells had fewer stimuli to respond to.
When a teenager makes the ‘stupid choice’, their brain is working exactly as designed Published: July 21, 2026 10.39am BST
https://theconversation.com/when-a-teenager-makes-the-stupid-choice-their-brain-is-working-exactly-as-designed-287503?utm_source=Live+Audience&utm_campaign=5aed9ee873-nature-briefing-daily-20260721&utm_medium=email&utm_term=0_-33f35e09ea-50432164
Teens’ bad decisions are not all irrational
Blaming teenagers’ undeveloped brains when they don’t choose the ‘sensible’ path — by retaliating against an insult in a school corridor, for example — does them a disservice, argues evolutionary criminologist Evelyn Svingen. “Teenagers do weigh up what they are doing. The costs that weigh most heavily on them are social, and adults consistently underestimate how heavy they are,” she writes. “The teenager who hits back in the corridor is running on an ancient programme.” She offers advice on how schools and parents can “create an environment where the rewarding thing to do and the sensible thing to do point in the same direction”.
New hope in the fight against cachexia — cancer’s deadly co-conspirator Scientists are getting closer to understanding the wasting and fatigue that often accompanies cancer. Treatments could be on the horizon. By Amber Dance
https://www.nature.com/articles/d41586-026-02228-7?utm_source=Live+Audience&utm_campaign=5aed9ee873-nature-briefing-daily-20260721&utm_medium=email&utm_term=0_-33f35e09ea-50432164
An influx of studies is shedding new light on cachexia, a syndrome that causes muscle wasting and reduced appetite and affects up to 80% of people with cancer. The research has repositioned the condition as a whole-body syndrome of metabolism gone haywire, with psychological symptoms as well as physical, and has unearthed clues as to how the brain orchestrates it. And a handful of companies, including pharma giant Pfizer, are testing medicines for cachexia, raising hope that a treatment might be on the horizon.
Huge study finds first genetic clues for borderline personality disorder Largest genetic analysis of the condition so far finds 11 linked locations in the human genome. By Miryam Naddaf
https://www.nature.com/articles/d41586-026-02220-1?utm_source=Live+Audience&utm_campaign=5aed9ee873-nature-briefing-daily-20260721&utm_medium=email&utm_term=0_-33f35e09ea-50432164
Researchers have identified the first evidence of genetic risk factors associated with borderline personality disorder (BPD).
The analysis, published in Nature Genetics on 20 July1, is the largest genome-wide association study (GWAS) of the condition so far. It identified 11 associated locations (or loci) in the human genome, and within or near these broad areas were nine functional genes that seem to be linked to BPD.
Researchers have identified 11 locations in the human genome, and nine functional genes in or near these areas, that seem to be linked to borderline personality disorder (BPD) — the first evidence of genetic risk factors associated with the condition. The findings come from the largest genome-wide association study of BPD so far, including data from more than 12,000 people with the condition. The study is “an extraordinary step up from where we’ve been previously, with virtually no research being conducted on the condition at scale,” says psychiatrist Andrew McIntosh.
Global, regional, and national trends in the morbidity gap and contributing diseases, injuries, and risk factors, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
Global, regional, and national trends in the morbidity gap and contributing diseases, injuries, and risk factors, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
Prof Simon I Hay, DSca,b Send email to sihay@uw.edu ∙ Paul Nam, MSa ∙ Haaris Saqib, MAa ∙ Susan A McLaughlin, PhDa ∙ Catherine Bisignano, MPHa ∙ Samuel M Ostroff, PhDa,c ∙ et al.
https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(26)00098-8/fulltext?dgcid=raven_jbs_etoc_feature_lanpub
Ebola: lessons from the past The Lancet Public Health +...
Ebola: lessons from the past
The Lancet Public Health
https://www.thelancet.com/journals/lanpub/issue/vol11no8/PIIS2468-2667(26)X2007-2
Five years of Greener NHS: improved carbon footprint assessment of the National Health Service in England ++
Five years of Greener NHS: improved carbon footprint assessment of the National Health Service in England
Robin Simpson, PhDa Send email to robin.simpson2@nhs.net ∙ Vimaladipa Imogen Tennison, MEnga ∙ Erik Episkopou, MSca ∙ Yashaswi Bagga, MSca ∙ Hiten Patel, BA Honsa ∙ Martin Caunt, MSca ∙ et al.
https://www.thelancet.com/journals/lanplh/article/PIIS2542-5196(26)00037-9/fulltext?dgcid=hubspot_update_feature_updatealerts_lanplh&utm_campaign=update-lanplh&utm_medium=email&_hsenc=p2ANqtz--gTxnWYYOnWPgL_HrGi-kH2pniuWqjRbMOOi8LmVY3SJ_v7x2VkL-0CF05p4397QqqBJ4xGiNq7Ttu_3_NDuB4KrP4cA&_hsmi=429429951&utm_content=428498656&utm_source=hs_email
Severe droughts and the tuberculosis and HIV care cascade in the Brazilian Amazon: a Bayesian, structural, interrupted time-series analysis of 24 years of surveillance data
Rodrigo C Menezes, MD PhDa,b,c,∗ ∙ Rodrigo M Telesa,b,d,∗ ∙ Isabella B B Ferreira, MDa,b,c,∗ ∙ Leandro S Garcia, MSce,f,∗ ∙ Jair S Pinheiro, MSce,f,g ∙ Tiago F Mota, PhDa,b ∙ et al.
https://www.thelancet.com/journals/lanplh/article/PIIS2542-5196(26)00032-X/fulltext?dgcid=hubspot_update_feature_updatealerts_lanplh&utm_campaign=update-lanplh&utm_medium=email&_hsenc=p2ANqtz-_a7OuHCqaEQ_5GhNFbrlT4i01jq0ZshKTDg4lFnOErUqQAe1quWHyBPIBQU9bTMgvDh0gOs4p-xz29-x6i6hNfGks63Q&_hsmi=429429951&utm_content=428498656&utm_source=hs_email
Editorial How we imagine the future matters The Lancet Planetary Health +...
Editorial
How we imagine the future matters
The Lancet Planetary Health
https://www.thelancet.com/journals/lanplh/issue/vol10no5/PIIS2542-5196(26)X2005-8
Suscribirse a:
Entradas (Atom)
.png)
.png)
